Phase 2 N=3 Clinical Trial Evaluating Rituximab in Ocular Cicatricial Pemphigoid
Ocular Cicatricial Pemphigoid
Primary: Number of Participants With no Evidence of Further Scarring (Fosters Staging) at 16 Weeks — 0 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=2 Efficacy and Safety of Omalizumab in Bullous Pemphigoid
Bullous Pemphigoid
Primary: Median Time From First Dose of Omalizumab Treatment to Cessation of New Blisters. — 6 weeks
Phase 2 N=10 A Study of the KIO-201 (Ocular Bandage Gel) for Improving Persistent Corneal Epithelial Defects
Persistent Corneal Epithelial Defect
Primary: Percentage of Patients Achieving Corneal Healing (<0.5 mm2 Lesion Size) of the Persistent Corneal Epithelial Defect at 4 Weeks — 5 Participants
Phase 3 N=745 Phase 3 Study of OTX-101 in the Treatment of Keratoconjunctivitis Sicca
Keratoconjunctivitis Sicca
Primary: Tear Production — 16.6; 9.2 Percentage of eyes
Phase 2 N=8 Rituximab in the Treatment of Patients With Bullous Pemphigoid
Bullous Pemphigoid
Primary: Primary Safety Endpoint — 0; 0; 1 participants
N/A N=12 Long-term Topical Cyclosporine for Atopic Keratoconjunctivitis
Atopic Keratoconjunctivitis
Primary: Ocular Symptoms and Signs Total Composite Score — 29.1; 4.7 units on a scale — p=0.002
Phase 4 N=11 Evaluation of the Efficacy of Topical Ophthalmic Steroids in a Modified Conjunctival Allergen Challenge (CAC) Model
Allergic Conjunctivitis
Primary: Ocular Itching Change From Baseline to Day 11 — -1.1; -0.45 units on a scale
Phase 2 N=80 Safety and Efficacy Study of CF101 to Treat Keratoconjunctivitis Sicca
Keratoconjunctivitis Sicca
Primary: Change From Baseline to Week 12 in Schirmer Test (ST) Score in Millimeters — 1.25; 3.81 Millimeters — p=0.027
Phase 2 N=75 Safety and Efficacy of CBT-001 Ophthalmic Solution in Patients With Pterygium
Pterygium
Primary: Pterygium Vascularity Change Assessed Using the Pterygium Hyperemia Grading Scale — 0; -0.8 grade — p=<0.001
Phase 2 N=20 Bandage Lenses in Treating Patients With Ocular Graft-Versus-Host Disease
Graft Versus Host Disease · Ophthalmologic Complications
Primary: Change in Patient-reported Symptoms Measured by the 8-point Lee Eye Subscale — 75.4; 63.2; 61.8; 56.3 units on a scale — p=0.01
Phase 4 N=35 Circadian Ocular Perfusion Pressure and Ocular Blood Flow
Glaucoma
Primary: Mean Change From Baseline in Overall Diastolic Ocular Perfusion Pressure at Week 6 — 2.6; 0.8 mmHg (millimeters of mercury)
N/A N=9 Ocular Sarcoidosis Open Label Trial of ACTHAR Gel
Ocular Sarcoidosis · Panuveitis · Anterior Uveitis
Primary: Percentage of Patients With Clinically Significant Improvement in Visual Acuity — 3 Participants
Phase 2 N=115 Safety and Efficacy of Cyclosporine Ophthalmic Emulsion in Patients With Primary Pterygium
Pterygium
Primary: Number of Pterygium Hyperemia Responders at Week 16 — 6; 8 Participants
Phase 4 N=36 Evaluation of the Efficacy of Topical Ophthalmic Steroids in a Modified Conjunctival Allergen Challenge (CAC) Model
Allergic Conjunctivitis
Primary: Ocular Itching at Baseline (Day 0) — 2.53; 3.08; 2.61; 2.5 units on a scale
N/A N=20 Optimizing the Ocular Surface Prior to Cataract Surgery
Corneal Dystrophy, Epithelial Basement Membrane
Primary: Change in Intraocular Lens Calculation — 1.56; 0.94 D
N/A N=25 Observational Study of Ocular Inflammation in Patients Undergoing a Pars Plana Vitrectomy
Vitrectomy
Primary: Percentage of Participants With Vitreous Cell Count of 0 — 88.0 Percentage of participants
Phase 4 N=35 VISmodegib for ORbital and Periocular Basal Cell Carcinoma
Carcinoma, Basal Cell
Primary: The Number of Patients With a Score of 21 or Greater by the Visual Assessment Weighted Score (VAWS). — 34 Participants
Phase 2 N=11 Evaluation of Safety, Efficacy and Pharmacodynamic Effect of Bertilimumab in Patients With Bullous Pemphigoid
Pemphigoid, Bullous
Primary: Number of Participants With Anti-Drug Antibodies — 0 Participants
Phase 4 N=16 Evaluation of Prednisolone in a Modified Conjunctival Allergen Challenge Model
Chronic Allergic Conjunctivitis
Primary: Inflammation Change From Baseline to Day 6 — -1.2; -0.19 score on a scale
Phase 2 N=102 Exploratory Study of OPC-12759 Ophthalmic Suspension
Keratoconjunctival Epithelial Disorder
Primary: Change in the Keratoconjunctival Staining Score From Baseline — -3.4; -3.1 scores on a scale — p=0.576
Phase 2 N=124 PRM-151 in the Prevention of Scarring Following Trabeculectomy
Glaucoma
Primary: Safety of Subconjunctival Injection — 274; 220; 166; 113 Number of occurrences
Phase 2 N=4 Ixekizumab in the Treatment of Bullous Pemphigoid
Bullous Pemphigoid · Pemphigoid
Primary: Cessation of Blister Formation — NA days
Phase 2 N=68 Vision Restoration With a Collagen Crosslinked Boston Keratoprosthesis Unit
Keratolysis
Primary: Time From Surgery to Device Loss or Replacement — 95; 34 median weeks from surgery to removal
Phase 3 N=258 An Open-Label Extension of a Phase 3 Study of OTX-101 in the Treatment of Keratoconjunctivitis Sicca
Keratoconjunctivitis Sicca
Primary: Adverse Events — 68; 81 Count of participants
Phase 2 N=31 Optiquel® as Corticosteroid-sparing Therapy for Chronic Noninfectious Uveitis
Uveitis
Primary: The Primary Outcome is the Time to Recurrence of Uveitis in Participants of Each Treatment Group, During or After Tapering of Oral Prednisone to a Dose of 7.5 mg/Day, or…
Phase 2 N=172 Efficacy and Safety of IBI-10090 in Ocular Surgery Patients
Inflammation Associated With Cataract Surgery
Primary: Anterior Chamber Cell Count at Day 8 Post-Treatment — 50; 51.8; 60.3 percentage of patients with ACC clearing
Phase 2 N=153 OCS-01 in Treating Inflammation and Pain in Post-cataract Patients
Inflammation Corneal · Pain, Postoperative
Primary: Number of Subjects With Absence of Anterior Chamber Cells (i.e. Score of '0') — 26; 34; 10 participants
Phase 4 N=82 Safety and Efficacy of Carboxymethylcellulose for Ocular Surface Integrity in Symptomatic Dry Eye
Dry Eye Syndromes · Keratoconjunctivitis Sicca
Primary: Change From Baseline in Global Ocular Staining Score at Day 35 — 5.4; 5.9; -1.8; -1.8 Number on a scale (score)
Phase 2 N=33 Treatment Safety and Efficacy of Pro-ocular™ 1% for Chronic Ocular Graft Following Allogeneic HSCT.
Chronic Ocular Graft-versus-host Disease
Primary: Modified SANDE Questionnaire - Frequency, Change From Baseline — -22.00; -4.59 score on a scale — p=0.0197
Phase 2 N=130 Safety and Efficacy of SJP-0035 Ophthalmic Solution in Patients With Moderate to Severe Corneal Epithelial Disorders
Corneal Epithelial Disorders
Primary: Number of Participants With Clearing of Corneal Fluorescein Staining at Week 5 at Week 5 — 5; 7; 12 Participants